Invention Grant
- Patent Title: Parvovirus cancer therapy and combination with chemotherapy
- Patent Title (中): 细小病毒癌症治疗与化疗相结合
-
Application No.: US12810457Application Date: 2008-12-23
-
Publication No.: US08414883B2Publication Date: 2013-04-09
- Inventor: Jean Rommelaere , Zahari Raykov , Joerg Schlehofer , Irina Kiprijanova , Tanja Heimberger , Assia Angelova , Karsten Geletneky , Marc Aprahamian
- Applicant: Jean Rommelaere , Zahari Raykov , Joerg Schlehofer , Irina Kiprijanova , Tanja Heimberger , Assia Angelova , Karsten Geletneky , Marc Aprahamian
- Applicant Address: DE Heidelberg DE Heidelberg
- Assignee: Deutsches Krebsforschungszentrum,Ruprecht-Karls-Universitaet Heidelberg
- Current Assignee: Deutsches Krebsforschungszentrum,Ruprecht-Karls-Universitaet Heidelberg
- Current Assignee Address: DE Heidelberg DE Heidelberg
- Agency: Crowell & Moring LLP
- Priority: EP07025216 20071228
- International Application: PCT/EP2008/011075 WO 20081223
- International Announcement: WO2009/083232 WO 20090709
- Main IPC: A61K48/00
- IPC: A61K48/00 ; A61K35/76 ; A61P1/18
Abstract:
Described is a pharmaceutical composition containing (a) a parvovirus and (b) a chemotherapeutic agent, preferably as separate entities. The parvovirus might be based on parvovirus H1, LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV), vectors based on the foregoing viral species, and/or cells capable of actively producing the foregoing viral species. The pharmaceutical composition is beneficial for the treatment of a tumor. Tumors for which a parvovirus or the adjunction of the invention has particular utility include glioma, medulloblastoma, meningioma and pancreatic cancer. Preferred chemotherapeutic agents are gemcitabine and Temozolodine.
Public/Granted literature
- US20110020287A1 Parvovirus Cancer Therapy and Combination with Chemotherapy Public/Granted day:2011-01-27
Information query
